Gene therapy in hemophilia: Clinical trials update

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 172-177

  White II, G C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Gene therapy; Hemophilia; Retrovirus

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COAGULIN B; GENE PRODUCT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; EXPERIMENTAL MODEL; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GOOD CLINICAL PRACTICE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RETROVIRUS;

EID: 0034923893     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616215     Document Type: Conference Paper

References (50)

1. Advances toward gene therapy for hemophilia at the millennium
2. Hepatic gene therapy for haemophilia B
3. Haemophilia A gene therapy
4. Problems and prospects in gene therapy for hemophilia
5. A new approach to gene therapy
6. Viral vector-mediated gene therapy for hemophilia B
7. Gene therapy - Promises, problems and prospects
8. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients
9. Clinical protocol of human gene transfer for hemophilia B
10. Non-viral gene transfer of blood coagulation factor VIII in patients with severe hemophilila A
11. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent
12. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency
13. An estimated frequency of endogenous insertional mutations in humans
14. Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: No evidence of germ line transduction
15. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
16. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
17. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy
18. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
19. A phase I trial of AAV-mediated muscle directed gene transfer for hemophilia B
20. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A
21. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
22. Studies in non-human primate and hemophilic dog models of a "gutless" adenovirus vector for treatment of hemophilia A
23. A proposed rAAV-liver directed clinical trial for hemophilia B
24. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
25. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
26. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titer
27. Hepatocyte growth factor expressed by a retrovirus-producing cell line enhances retroviral transduction of primary hepatocytes: Implications for in vivo gene transfer
28. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes
29. Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice
30. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
31. In vivo gene delivery by lentiviral vectors
32. Gene transfer vectors derived from equine infectious anemia virus
33. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
34. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors
35. Foamy virus vectors
36. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
37. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
38. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers
39. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region
40. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX
41. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
42. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
43. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
44. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
45. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
46. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
47. Heparin sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions
48. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR
49. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein
50. Gene therapy: The need for basic science